CWHM-1611

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameCWHM-1611
Drug Alias NameVLA-4 inhibitor (Magenta Therapeutics/Saint Louis University School of Medicine/Washington University School of Medicine)CWHM-1611
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-4/beta-1 antagonists
TargetsIntegrin alpha-4/beta-1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMagenta Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWashington UniversityMagenta Therapeutics IncSaint Louis University
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A